stockrow
Monday 9 November 2026
Export CUE’s income statement to Excel — free account
Cue Biopharma, Inc.
CUECue Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, up 195.7% from fiscal 2024.
- Revenue
- +166.7%
- EPS
- −793.2%
- Free cash flow
- −742.7%
Quarter to June 2026, against a year earlier
18.73
0.72
+4.00%
Follow CUE
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(195.19%) | (121.11%) | (138.52%) | (1,603.48%) | |
Piotroski F-Score |
3 | 5 | 4 | 3 | |
| (98.58%) | (71.51%) | (73.49%) | (459.60%) | ||
ROIC |
0.00% | 0.00% | (294.07%) | 0.00% | |
Return on Tangible Assets |
(355.43%) | (112.10%) | (101.21%) | (2,899.43%) | |
Average Days of Receivables |
19.90 | 73.70 | 59.67 | 52.12 | |
Free Cash Flow per Share |
(8.87) | (6.04) | (5.11) | (7.91) | |
Free Cash Flow |
(29.80) | (21.82) | (24.56) | (50.13) | |
Capital Expenditures |
(0.16) | (0.14) | (0.11) | (0.08) | |
| Other line items | |||||
Cash ROIC |
(84.38%) | (39.93%) | (62.91%) | (254.14%) | |
Accounts Receivable Turnover |
6.36 | 6.32 | 10.40 | 12.74 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
399.94% | 137.42% | 110.27% | 205.00% | |
Selling, General and Administrative Expense of Revenue |
236.79% | 59.14% | 49.56% | 156.98% | |
Share Based Compensation of Revenue |
80.23% | 17.27% | 10.55% | 69.13% | |
Interest Coverage |
(95.41) | (74.38) | (84.15) | (511.22) | |
Operating CF/Net income |
0.79 | 0.82 | 1.25 | 0.31 | |
Depreciation/Fixed assets |
0.76 | 3.25 | 4.19 | 4.58 | |
Capex/Depreciation |
(0.68) | (0.17) | (0.09) | (0.07) | |
Revenue per Share |
2.11 | 7.61 | 6.81 | 5.94 | |
Operating CF per Share |
(8.82) | (6.01) | (5.09) | (7.89) | |
Capex per Share |
(0.05) | (0.04) | (0.02) | (0.01) | |
Capex to Sales |
0.02 | 0.01 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026